PMID- 20210681
OWN - NLM
STAT- MEDLINE
DCOM- 20100617
LR  - 20101118
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 11
IP  - 5
DP  - 2010 Apr
TI  - Impact of managing atherogenic dyslipidemia on cardiovascular outcome across 
      different stages of diabetic nephropathy.
PG  - 723-30
LID - 10.1517/14656560903575654 [doi]
AB  - IMPORTANCE OF THE FIELD: The prevalence of chronic kidney disease (CKD) and type 
      2 diabetes mellitus (T2DM) is increasing. In turn, both CKD and T2DM are 
      associated with increased risk of vascular events and progression to end-stage 
      kidney disease (ESKD). In patients with DM, statin treatment can significantly 
      improve estimated glomerular filtration rate (eGFR) or delay eGFR decline as well 
      as significantly reduce CVD morbidity and mortality. In contrast, statins do not 
      seem to decrease events in patients with advanced decline in kidney function. 
      AREAS COVERED IN THIS REVIEW: This review considers the effects of statins and 
      other lipid lowering drugs on kidney function and vascular events in patients 
      with CKD and T2DM. WHAT THE READER WILL GAIN: Greater awareness of the links 
      between CKD, T2DM, kidney function and vascular risk as well as the role of 
      lipid-lowering drugs (mainly statins) in this field. TAKE HOME MESSAGE: Current 
      evidence points towards the need to prescribe statins in patients with T2DM 
      before a major decline in kidney function occurs.
FAU - Athyros, Vasilios G
AU  - Athyros VG
AD  - Second Propedeutic Department of Internal Medicine, Aristotle University of 
      Thessaloniki, Hippocration Hospital, Medical School, Thessaloniki, Greece.
FAU - Mitsiou, Eydoxia K
AU  - Mitsiou EK
FAU - Tziomalos, Konstantinos
AU  - Tziomalos K
FAU - Karagiannis, Asterios
AU  - Karagiannis A
FAU - Mikhailidis, Dimitri P
AU  - Mikhailidis DP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Hypolipidemic Agents)
SB  - IM
MH  - Atherosclerosis/complications/drug therapy
MH  - Cardiovascular Diseases/etiology/mortality/prevention & control
MH  - Diabetes Mellitus, Type 2/complications
MH  - Diabetic Nephropathies/*complications
MH  - Dyslipidemias/complications/*drug therapy
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Hypolipidemic Agents/pharmacology/*therapeutic use
MH  - Kidney Failure, Chronic/complications
MH  - Severity of Illness Index
RF  - 60
EDAT- 2010/03/10 06:00
MHDA- 2010/06/18 06:00
CRDT- 2010/03/10 06:00
PHST- 2010/03/10 06:00 [entrez]
PHST- 2010/03/10 06:00 [pubmed]
PHST- 2010/06/18 06:00 [medline]
AID - 10.1517/14656560903575654 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2010 Apr;11(5):723-30. doi: 10.1517/14656560903575654.